- Home
- PWUPU vs TNGX Comparison
PWUPU vs TNGX Comparison
Compare PWUPU & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWUPU
- TNGX
- Stock Information
- Founded
- PWUPU N/A
- TNGX 2014
- Country
- PWUPU
- TNGX United States
- Employees
- PWUPU N/A
- TNGX N/A
- Industry
- PWUPU
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PWUPU
- TNGX Health Care
- Exchange
- PWUPU NYSE
- TNGX Nasdaq
- Market Cap
- PWUPU N/A
- TNGX 735.0M
- IPO Year
- PWUPU N/A
- TNGX N/A
- Fundamental
- Price
- PWUPU $11.51
- TNGX $6.64
- Analyst Decision
- PWUPU
- TNGX Strong Buy
- Analyst Count
- PWUPU 0
- TNGX 8
- Target Price
- PWUPU N/A
- TNGX $15.14
- AVG Volume (30 Days)
- PWUPU N/A
- TNGX 885.7K
- Earning Date
- PWUPU N/A
- TNGX 11-06-2024
- Dividend Yield
- PWUPU N/A
- TNGX N/A
- EPS Growth
- PWUPU N/A
- TNGX N/A
- EPS
- PWUPU N/A
- TNGX N/A
- Revenue
- PWUPU N/A
- TNGX $42,509,000.00
- Revenue This Year
- PWUPU N/A
- TNGX $18.15
- Revenue Next Year
- PWUPU N/A
- TNGX N/A
- P/E Ratio
- PWUPU N/A
- TNGX N/A
- Revenue Growth
- PWUPU N/A
- TNGX 26.16
- 52 Week Low
- PWUPU N/A
- TNGX $6.33
- 52 Week High
- PWUPU N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- PWUPU 43.76
- TNGX 37.15
- Support Level
- PWUPU $11.51
- TNGX $6.83
- Resistance Level
- PWUPU $13.90
- TNGX $7.47
- Average True Range (ATR)
- PWUPU 0.86
- TNGX 0.37
- MACD
- PWUPU -0.19
- TNGX 0.11
- Stochastic Oscillator
- PWUPU 1.97
- TNGX 27.31
About PWUPU POWERUP ACQUISITION CORP UNIT 1 COM CL A & 1/2 RED WT(18/02/2032)
PowerUp Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.